HoLEP 对良性前列腺增生的疗效及安全性观察.

Objective: To observe the clinical efficacy and safety of the HoLEP treatment of BPH. Methods: 102 BPH patients with HoLEP clinical data were collected in our hospital. Age of the BPH patients, size of their removal gland, surgical blood loss, as well as the Qmax, the Pdet/ Qmax, IPSS and QOLS before and after operation were analyzed. Then another 100 BPH patients treated with TURP clinical data in our hospital were selected and complications of the patients were compared between the two groups. Results : The age of 102 BPH patients was (71.58± 9.74) years. The removal glands of patients was (84.32± 36.39)g. The loss of surgical blood was (146± 24.68) mL. Before the operation, the Qmax was(8.37± 5.28) mL/s, Pdet/ Qmax (72.93± 26.49) cm H2O, IPSS (28.8± 5.98), and QOLS (5.8± 0.46). After the operation, the Qmax of patients was (24.77± 5.89) mL/s, Pdet/ Qmax of patients (42.35± 10.37) cm H2O, IPSS (9.4± 1.28), and QOLS (2.8± 0.28), which means that Qmax increased significantly (P<0.05), while Pdet/ Qmax, IPSS score and QOLS were significantly lower (P<0.05). Complications occurred significantly less with BPH patients of HoLEP treatment than that with TURP (P<0.05). HoLEP is a safe and effective minimally invasive surgery in the treatment of BPH. [ABSTRACT FROM AUTHOR]